SOUTH SAN FRANCISCO, CALIFORNIA, April 30, 2026
IDEAYA Biosciences has announced that the U.S. Food and Drug Administration (FDA) has agreed to review its New Drug Application (NDA) for darovasertib in combination with crizotinib under the Oncology Center of Excellence (OCE) Real-Time Oncology Review (RTOR) program. This milestone follows positive Phase 2/3 registrational data from the OptimUM-02 trial, where the combination therapy demonstrated statistically significant improvement in progression-free survival (PFS) and reduced the risk of disease progression by 58% in patients with first-line HLA*A2-negative metastatic uveal melanoma (mUM). The company plans to initiate the RTOR pre-submission process in May 2026, with full NDA submission expected in the second half of the year, highlighting a critical step toward accelerated regulatory approval and patient access.
Phase 2/3 Data Demonstrates Strong Clinical Benefit
The OptimUM-02 clinical trial represents a pivotal advancement in precision oncology, delivering compelling evidence for the efficacy of the darovasertib combination therapy. The study achieved its primary endpoint, with patients receiving the combination therapy experiencing a median progression-free survival of 6.9 months compared to 3.1 months in the investigator’s choice therapy arm. Additionally, the trial reported an overall response rate (ORR) of 37.1%, including complete responses, significantly outperforming the comparator group.
These results underscore the therapy’s potential to address a critical unmet medical need in metastatic uveal melanoma, a rare and aggressive cancer with limited treatment options. Importantly, the combination demonstrated a manageable safety profile, supporting its advancement toward regulatory submission and potential commercialization.
RTOR Program Enables Accelerated Regulatory Review
Advertisement
The FDA’s Real-Time Oncology Review (RTOR) program is designed to streamline the regulatory review process by allowing companies to submit clinical data in stages, enabling earlier evaluation of key findings before the full NDA submission is completed. IDEAYA’s acceptance into this program reflects the strength and quality of its clinical data, as well as the therapy’s potential to deliver meaningful clinical benefit.
Through RTOR, the company aims to accelerate the availability of innovative cancer treatments, reducing the time required for regulatory decision-making while maintaining rigorous safety and efficacy standards. This approach aligns with Good Clinical Practice (GCP) and regulatory innovation frameworks, reinforcing the importance of efficient, data-driven drug development pathways in modern oncology.
Expanding Precision Oncology and Future Pipeline Development
IDEAYA’s progress with darovasertib highlights its broader strategy of developing targeted therapies based on genetic drivers of cancer, integrating biomarker-driven approaches with advanced drug discovery platforms. In addition to the current NDA submission, the company is exploring additional clinical trials across different patient populations, including HLA*A2-positive mUM and earlier-stage disease settings. The upcoming presentation of full trial results at the ASCO 2026 Annual Meeting is expected to further validate the therapy’s clinical impact and support ongoing regulatory interactions.
From a GxP perspective, the program demonstrates strong adherence to data integrity, clinical validation, and regulatory compliance, ensuring that the therapy meets the highest standards for quality and patient safety. As the demand for personalized cancer therapies continues to grow, IDEAYA’s innovative approach positions it as a leader in next-generation oncology drug development, with the potential to significantly improve outcomes for patients with rare and difficult-to-treat cancers.
Source: IDEAYA Biosciences press release
